Related Experiment Video
Updated: Jul 11, 2025
10:19
Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
1.3K
Rapid Access to Potent Bispecific T Cell Engagers Using Biogenic Tyrosine Click Chemistry
Irene Shajan1, Léa N C Rochet2, Shannon R Tracey3
1Laboratory of Organic Chemistry, Wageningen University & Research, Stippeneng 4, Wageningen 6807 WE, The Netherlands.
Bioconjugate Chemistry
|November 14, 2023
Summary
Researchers developed a novel chemoenzymatic method to create potent bispecific antibodies for cancer therapy. This non-genetic approach modifies existing antibodies, enabling precise T cell engagement and tumor cell killing at picomolar concentrations.
Area of Science:
- Biotechnology
- Immunology
- Chemical Biology
Background:
- Bispecific antibodies are promising cancer therapeutics, engaging T cells to target tumor cells.
- Existing methods for bispecific antibody development often involve complex genetic engineering.
- A non-genetic, readily applicable method to create bispecific antibodies from native antibodies is needed.
Purpose of the Study:
- To develop a non-genetic method for converting native IgG1 antibodies into potent bispecific T cell engagers.
- To demonstrate the tumor-killing capability of synthetically generated bispecific antibodies.
- To establish a modular and efficient approach for producing tunable bispecific antibody constructs.
Main Methods:
- Application of a biogenic, tyrosine-based click reaction for antibody modification.
- Chemoenzymatic modification of native IgG1 antibodies.
- Generation of synthetic bispecific antibody constructs.
Main Results:
- The developed method successfully generated synthetic bispecific antibody constructs.
- These constructs exhibited potent tumor-killing capability at picomolar concentrations.
- Covalent linkage of antibody components was essential for biological activity.
Conclusions:
- The chemoenzymatic approach provides a facile, non-genetic route to potent bispecific antibodies.
- This modular method utilizes therapeutically approved biomolecules for efficient production.
- The synthetic bispecific antibodies offer tunable efficacy with significant therapeutic potential for cancer treatment.
